News

UK’S National Institute for Health and Care Excellence (NICE) Selects CEL-SCI’s Multikine as Potential New Standard of Care for Head & Neck Cancer

VIENNA, Va.--(BUSINESS WIRE)--$CVM #Multikine--CEL-SCI Corporation (NYSE American: CVM) today announced that the British National Institute for Health and Care Excellence…

2 years ago

Resurgens Technology Partners Invests in Valant – An Industry Leader in Software Supporting the Behavioral Health Industry

SEATTLE--(BUSINESS WIRE)--Resurgens Technology Partners, a software-focused private equity firm, today announced its investment in Valant, a cloud-based EHR for behavioral…

2 years ago

Resurgens Technology Partners Invests in Valant – An Industry Leader in Software Supporting the Behavioral Health Industry

SEATTLE--(BUSINESS WIRE)--Resurgens Technology Partners, a software-focused private equity firm, today announced its investment in Valant, a cloud-based EHR for behavioral…

2 years ago

Gain Therapeutics to Participate in FORCE Family Office Event with Zacks Small-Cap Research

BETHESDA, Md., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (the “Company”), a biotechnology company leading the…

2 years ago

Stemtech Continues to Demonstrate Remarkable Growth and Innovation in 2023

Company Achieves NEW Rank Advancements, Acknowledges Sales Directors, and Sets Course for Future ExpansionNAPLES, FL / ACCESSWIRE / December 4,…

2 years ago

FDA Approves Renewal of Canalevia-CA1, Jaguar Health’s Drug for Chemotherapy-Induced Diarrhea in Dogs

Canalevia®-CA1 is the first and only treatment for chemotherapy-induced diarrhea (CID) in dogs to receive any type of approval from…

2 years ago

Spire Healthcare Advances Pathology Services With Tribun Health Partnership

PARIS, FRANCE / ACCESSWIRE / December 4, 2023 / Spire Healthcare, a leading independent healthcare group in the United Kingdom,…

2 years ago

Daré Bioscience Announces Commencement of Phase 3 Study of Ovaprene®, an Investigational Hormone-Free Monthly Intravaginal Contraceptive

Ovaprene has the Potential to be the First FDA-Approved Monthly, Self-Administered, Hormone-Free Contraceptive ProductSAN DIEGO, Dec. 04, 2023 (GLOBE NEWSWIRE)…

2 years ago

IntelGenx Announces Changes to its Board of Directors

SAINT LAURENT, Quebec, Dec. 04, 2023 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX: IGX) (OTCQB: IGXT) (the “Company” or “IntelGenx”) announces…

2 years ago

Cogent Biosciences to Host Investor Webcast on December 11, 2023 at 8:00 AM ET to Review Clinical Data Being Presented at American Society of Hematology (ASH) Annual Meeting

- Event to review initial clinical data from SUMMIT Part 1a in patients with Nonadvanced Systemic Mastocytosis (NonAdvSM) - Additional…

2 years ago